{"product_id":"rush-university-medical-center-biennial-cardio-oncology-symposium-2021","title":"Rush University Medical Center Biennial Cardio-Oncology Symposium 2021","description":"\u003cdiv class=\"prod-edition\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"form-control-plaintext\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003ch3 class=\"product_title entry-title\"\u003eRush University Medical Center Biennial Cardio-Oncology Symposium 2021\u003c\/h3\u003e\n\u003cp\u003eRush University Medical Center Biennial Cardio-Oncology Symposium 2021\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e Include: 19 videos, size: 5.2 GB\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCardiovascular disease and cancer are the #1 and #2 causes of death in the United States. Both conditions involve many variables and their study is constant and diffuse. Cardio-oncology is a nascent field that focuses on preventing adverse cardiovascular outcomes in patients with active cancer; and improving the overall cardiovascular health of cancer survivors.\u003c\/p\u003e\n\u003cp\u003eThis involves a specific understanding of interactions between cancer and the cardiovascular system; as well as intrinsic knowledge of cancer therapeutic agents including chemotherapy, radiation therapy, and newer targeted therapies which include immunotherapy, such as immune checkpoint inhibitors and Car-T cell therapy.\u003c\/p\u003e\n\u003cp\u003eFurthermore, recent developments in the medical management of cardiac disease (such as SGLT-2 inhibitors and ivabradine) present new therapeutic options for affected cancer patients and survivors. With such rapid change, clinicians often find it difficult to remain up-to-date with the best means of identifying and treating patients. The purpose of this program is to familiarize primary care providers, hospitalists, oncologists, cardiologists, advanced practice providers, pharmacists and trainees with the updated treatment of cardiac conditions seen in cancer patients and survivors.\u003c\/p\u003e\n\u003cp\u003eThis activity has been planned for Primary Care Providers, Hospitalists, Oncologists, Cardiologists, Advanced Practice Providers, Pharmacists, Nurses and Trainees interested in learning about the field of Cardio-Oncology.\u003c\/p\u003e\n\u003cp\u003eRush University Medical Center Biennial Cardio-Oncology Symposium 2021\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e\u003cstrong\u003eEducational Objectives\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eAt the conclusion of this activity, participants should be better able to:\u003c\/p\u003e\n\u003col\u003e\n\u003cli class=\"p1\"\u003e1. Define the risks of cancer treatment-related cardiac dysfunction for patients who have undergone therapy for cancer.\u003c\/li\u003e\n\u003cli class=\"p1\"\u003e2. Provide some knowledge of cardiovascular effects of newer cancer therapies; as well as the potential use of newer cardiac drugs for the management of cardiovascular complications associated with cancer therapy.\u003c\/li\u003e\n\u003cli class=\"p1\"\u003e3. Implement strategies for early detection, correction of cardiac risk factors and close, as well as long-term cardiovascular monitoring in order to reduce the effects of cardiotoxicity (including arrhythmias, heart failure, severe hypertension, valvular heart disease, pericardial disease, and autonomic dysfunction) for patients who are at risk for cancer treatment-related cardiac dysfunction.\u003c\/li\u003e\n\u003cli class=\"p1\"\u003e4. Assess appropriate and effective treatment strategies and referrals for patients who have (or are at risk for) long-term toxicity-related cardiac dysfunction, including heart failure, valvular dysfunction, hypertension, and autonomic dysfunction.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp\u003eRush University Medical Center Biennial Cardio-Oncology Symposium 2021\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e Topics:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eBiomarkers for Monitoring and Prevention in Cancer Heart Disease- Traditional and Innovative Perspectives.mp4\u003c\/li\u003e\n\u003cli\u003eCancer Therapeutic Agents of Arrhythmia- Targeted Treatments Based on Possible Mechanisms.mp4\u003c\/li\u003e\n\u003cli\u003eCardio-Oncology Case Studies Discussion on the Management of Cardiotoxicity Associated with Anthracyclines.mp4\u003c\/li\u003e\n\u003cli\u003eCardiovascular Perspectives on Stem Cell Transplant and CAR T Cell Therapy- The Old and the New for Assessment and Management.mp4\u003c\/li\u003e\n\u003cli\u003eCardiovascular Toxicities of Chemotherapies- Challenging the Paradigm for Monitoring During and After Treatment.mp4\u003c\/li\u003e\n\u003cli\u003eCurrent and New FDA-Approved Management Strategies for Multiple Myeloma and Cardiac Amyloidosis.mp4\u003c\/li\u003e\n\u003cli\u003eExpanding Research of Immune Checkpoint Inhibitors and Contemplations for the Future- Cardio-Immunology Is the New Cardio-Oncology.mp4\u003c\/li\u003e\n\u003cli\u003eHow Cancers and Heart Disease Intersect- A Cardiologist’s Perspective.mp4\u003c\/li\u003e\n\u003cli\u003eHow Cancers and Heart Disease Intersect- An Oncologist’s Perspective.mp4\u003c\/li\u003e\n\u003cli\u003eHow to Make a Difference in Patient Care- A Cardiologist’s Perspective.mp4\u003c\/li\u003e\n\u003cli\u003eHow to Make a Difference in Patient Care- An Oncologist’s Perspective.mp4\u003c\/li\u003e\n\u003cli\u003eLessons Learned From the Cardio-Oncology in the Wake of COVID-19.mp4\u003c\/li\u003e\n\u003cli\u003eNovel Imaging Paradigms for Characterization of Cardiovascular Toxicities Associated With Cancer Therapy.mp4\u003c\/li\u003e\n\u003cli\u003eOverview of Short and Long-Term Management of Cardiovascular Disease in the Cancer Patient- Research-Driven Guidance for the Clinician.mp4\u003c\/li\u003e\n\u003cli\u003ePanel Discussion on Cardio-Oncology Cases- mRCC, HER2+BC, Stage 23 Endometrioid Adenocarcinoma, HR-CLL.mp4\u003c\/li\u003e\n\u003cli\u003eThe Modern Era of Radiation Therapy- Contemporary Approaches to Modulating Cardiovascular Toxicities.mp4\u003c\/li\u003e\n\u003cli\u003eThe Triangle of Cancer, Chemotherapy, and Vascular Insult- Future Concepts for Management.mp4\u003c\/li\u003e\n\u003cli\u003eUnderstanding the Biology of Cancer Treatment-Induced Cardiac Toxicity.mp4\u003c\/li\u003e\n\u003cli\u003eVEGF-TKIs as Novel Mechanisms Predictors of Hypertension- Management Strategies.mp4\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003c\/div\u003e\n","brand":"My Store","offers":[{"title":"Default Title","offer_id":42954588258402,"sku":"MED-AMB06650","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/5897468797739188880_121.jpg?v=1779380274","url":"https:\/\/meducourse.com\/products\/rush-university-medical-center-biennial-cardio-oncology-symposium-2021","provider":"Meducourse","version":"1.0","type":"link"}